POS1239 POSITIVE IMPACT OF THE FIRST LOCKDOWN IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM
Authors: C. Gaujoux-Viala, C. Traverson, E. Filhol, C. Daien, S. Laurent-Chabalier, B. Combe, C. Lukas, J. Morel, C. Hua
Journal: Annals of the Rheumatic Diseases (2021)

Background: Since the beginning of 2020, the COVID-19 pandemic has caused a considerable amount of fear, worry and concern in the general population and among certain groups such as the elderly, healthcare providers and people with pre-existing conditions in particular. Our patients suffering from chronic inflammatory rheumatism (CIR), a group of autoimmune pathologies treated by immunosuppressant medication, are particularly concerned. Actions taken – particularly quarantine and its effects on the normal activities, habits or livelihoods of many people – also have a significant impact. There is little information on the impact of the lockdown in patients with CIR with data measured prospectively, in a standardized way, before and during the first lockdown period. Objectives: The objective of this ancillary study was to evaluate the psychological impact of the first lockdown period (anxiety, depression, sleep disorders, catastrophizing...) as well as the evolution of disease activity in patients suffering from CIR. Methods: At two French university hospitals, adult patients with rheumatoid arthritis (RA) according to the ACR-EULAR 2010 criteria, spondyloarthritis (SpA) fulfilling the ASAS 2009 criteria and psoriatic arthritis (PsA) according to the Caspar 2006 criteria were consecutively included in the Catastrophism in Chronic Inflammatory Rheumatism (CRIC) study from September 2019. Sociodemographic data, information on the disease and its treatments were collected as well as questionnaires on disease activity (DAS28, CDAI, BASDAI), function (HAQ), quality of life (SF12, EQ5D), anxiety and depression (HADS, GAD7), insomnia (ISI) and catastrophizing scores (PCS). These data were collected prospectively at baseline, 3, 6 and 12 months. In this ancillary study, data from patients with an assessment before and during lockdown were analyzed. Statistical analyses were descriptive with a paired Student’s T-test. Results: In all, 140 patients (49 RA, 69 SpA and 22 PsA) were evaluated before and during lockdown. The median age was 53.5 [44-63] years and 60.7% were women; 74 patients (53.2%) were professionally active and 102 (72.9%) were living as couples. The majority of patients (92.9 %) had a disease lasting more than 2 years. Concerning treatments, 63 (45%) were treated by bDMARD monotherapy, 40 (28.5%) by bDMARD+ csDMARD, 17 (12.1%) by csDMARD monotherapy and 2 patients by tsDMARD; 90.7% were not taking any corticosteroids and 8.6% were taking ≤5 mg/d; 30% were on NSAIDs. When comparing before and during lockdown, pain, tender joint count, swollen joint count, disease activity (CDAI, BASDAI) and function (HAQ, SF12 physical component) were similar. However, there was a significant improvement in psychological status, anxiety (HADS, GAD7), the mental component of SF12, catastrophizing and overall quality of life (EQ5D) (see Table 1 below). Conclusion: There are very few prospective, standardized data on the impact of lockdown in patients with CIR with an assessment before and during the first lockdown period. In patients with CIR, the first lockdown period had no impact on the activity of the disease and was well experienced psychologically with less anxiety and an improvement in quality of life. Table 1. Outcome ( N ) 140 CIR: 49 RA, 69 SpA, 22 PsA Before lockdown Mean (SD) During lockdown Mean (SD) Mean change (SD ) P Pain VAS (138 ) 39.4 (25.3) 39.4 (25.0) -0.28 (27.1) NS TJC (57 ) 4.0 (6.8) 4.7 (4.4) 0.7 (5.9) NS SJC (56 ) 1.0 (2.6) 1.6 (1.7) 0.5 (2.4) NS CDAI (36 ) 11.7 (1.4) 12.3 (7.5) 1.2 (8.7) NS BASDAI (84 ) 4.7 (1.9) 4.9 (2.0) 0.14 (1.4) NS HAQ (135 ) 0.72 (0.57) 0.72 (0.53) 0.03 (0.33) NS SF12 mental (136 ) 32.7 (8.7 ) 36.2 (8.4 ) 3.46 (8.01 ) &lt;0.0001 GAD-7 (anxiety ) (135 ) 7.7 (5.5 ) 5.0 (5.3 ) -1.73 (0.40 ) &lt;0.0001 HADS anxiety (137 ) 8.5 (3.9 ) 7.8 (3.9 ) -0.64 (2.91 ) 0.0113 EQ5D (139 ) 0.55 (0.31 ) 0.61 (0.29 ) 0.06 (0.24 ) 0.0078 PCS (catastrophizing ) (137 ) 18.9 (13.3 ) 15.9 (11.1 ) -3.10 (9.60 ) 0.0003 Disclosure of Interests: None declared